Topics:

Sunesis and MMRC collaborate to study SNS-032 in myeloma

Sunesis and MMRC collaborate to study SNS-032 in myeloma

SOUTH SAN FRANCISCO, California—Sunesis Pharmaceuticals, Inc. and the Multiple Myeloma Research Consortium (MMRC) have entered into a collaboration to evaluate Sunesis' SNS-032 for the treatment of multiple myeloma. SNS-032 is a potent, selective inhibitor of cyclin-dependent kinases (CDKs) 2, 7, and 9 that inhibits both cell cycle progression and transcription.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.